Published in Eur J Heart Fail on June 01, 2004
Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal (2012) 1.37
Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer (2009) 0.94
Zebrafish heart failure models for the evaluation of chemical probes and drugs. Assay Drug Dev Technol (2013) 0.93
Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. PLoS One (2014) 0.78
The Alpha-1A Adrenergic Receptor in the Rabbit Heart. PLoS One (2016) 0.75
Experimental animal model for anthracycline-induced heart failure. Eur J Heart Fail (2004) 0.75
An Upgrade on the Rabbit Model of Anthracycline-Induced Cardiomyopathy: Shorter Protocol, Reduced Mortality, and Higher Incidence of Overt Dilated Cardiomyopathy. Biomed Res Int (2015) 0.75
Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med (2014) 3.10
Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep (2009) 1.97
SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol (2005) 1.25
Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol (2010) 1.21
In vitro analysis of iron chelating activity of flavonoids. J Inorg Biochem (2011) 1.16
The role of reactive oxygen and nitrogen species in cellular iron metabolism. Free Radic Res (2006) 1.14
Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity. Free Radic Biol Med (2010) 0.98
Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf (2005) 0.95
Proteomic insights into chronic anthracycline cardiotoxicity. J Mol Cell Cardiol (2011) 0.93
In vitro interactions of coumarins with iron. Biochimie (2010) 0.90
Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. J Sep Sci (2005) 0.88
Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology (2007) 0.87
A study of potential toxic effects after repeated 10-week administration of a new iron chelator--salicylaldehyde isonicotinoyl hydrazone (SIH) to rabbits. Acta Medica (Hradec Kralove) (2003) 0.87
Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J Pharmacol Exp Ther (2008) 0.86
Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways. J Pharmacol Exp Ther (2012) 0.84
In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology (2007) 0.82
Novel method for rapid copper chelation assessment confirmed low affinity of D-penicillamine for copper in comparison with trientine and 8-hydroxyquinolines. J Inorg Biochem (2013) 0.82
Iron reduction potentiates hydroxyl radical formation only in flavonols. Food Chem (2012) 0.82
New iron chelators in anthracycline-induced cardiotoxicity. Cardiovasc Toxicol (2007) 0.81
Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals (2005) 0.81
Role of type II pneumocytes in pathogenesis of radiation pneumonitis: dose response of radiation-induced lung changes in the transient high vascular permeability period. Exp Toxicol Pathol (2004) 0.81
Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits. Hum Exp Toxicol (2002) 0.80
The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity. Chem Res Toxicol (2009) 0.80
Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS One (2013) 0.80
The effects of lactoferrin in a rat model of catecholamine cardiotoxicity. Biometals (2008) 0.80
Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J Pharmacol Exp Ther (2006) 0.80
Myocardial regulatory proteins and heart failure. Eur J Heart Fail (2005) 0.79
In vitro platelet antiaggregatory properties of 4-methylcoumarins. Biochimie (2012) 0.78
Cardiac biomarkers in a model of acute catecholamine cardiotoxicity. Hum Exp Toxicol (2009) 0.78
HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.78
Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity. Can J Physiol Pharmacol (2012) 0.77
Effect of sodium 2,3-dimercaptopropane-1-sulphonate (DMPS) on chronic daunorubicin toxicity in rabbits: comparison with dexrazoxane. Acta Medica (Hradec Kralove) (2002) 0.77
Cardiovascular effects of coumarins besides their antioxidant activity. Curr Top Med Chem (2015) 0.77
Mathematical calculations of iron complex stoichiometry by direct UV-Vis spectrophotometry. Bioorg Chem (2013) 0.77
Direct administration of rutin does not protect against catecholamine cardiotoxicity. Toxicology (2008) 0.76
Cardiac troponins following repeated administration of an iron chelator--salicylaldehyde isonicotinoyl hydrazone (SIH)--in rabbits. Acta Medica (Hradec Kralove) (2003) 0.76
Pharmacological potential of endothelin receptors agonists and antagonists. Acta Medica (Hradec Kralove) (2005) 0.76
The fate of iron in the organism and its regulatory pathways. Acta Medica (Hradec Kralove) (2005) 0.76
The neurodegenerative process in a neurotoxic rat model and in patients with Huntington's disease: histopathological parallels and differences. Acta Histochem (2010) 0.76
Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology (2013) 0.76
Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats. Shock (2014) 0.76
Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity. Hemoglobin (2008) 0.75
Daunorubicin does not induce immunohistochemically detectable endothelial dysfunction in rabbit aorta and femoral artery. Histol Histopathol (2011) 0.75
Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy. Cancer Chemother Pharmacol (2003) 0.75
In vitro characteristics of 1-phenyl-3-methyl-4-acylpyrazol-5-ones iron chelators. Biochimie (2011) 0.75
A pilot study of matrix metalloproteinases on the model of daunorubicin-induced cardiomyopathy in rabbits. Acta Medica (Hradec Kralove) (2007) 0.75
Troponins in experimental studies. Acta Medica (Hradec Kralove) (2002) 0.75
Oral administration of quercetin is unable to protect against isoproterenol cardiotoxicity. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Endothelins and sarafotoxins: peptides of similar structure and different function. Acta Medica (Hradec Kralove) (2004) 0.75